RayzeBio’s Post

At RayzeBio, a Bristol Myers Squibb Company, we are on a mission to become the global leader in radiopharmaceuticals. With a history rooted in biotech, now part of the best-in-class capabilities of Bristol Myers Squibb, we are harnessing the power of targeted radioisotopes to focus on improving survival of people living with cancer.   We’re expanding our innovative and patient-focused team in San Diego and Indianapolis. View our open roles here: https://lnkd.in/gKwu3cn3

As of today, RayzeBio, Inc. is officially part of Bristol Myers Squibb! We are excited to continue our mission and look forward to delivering breakthrough therapies through our differentiated radiopharmaceutical platform as part of BMS. Follow our progress Bristol Myers Squibb

We are excited to announce our proposed acquisition by Bristol Myers Squibb. Our leading position in radiopharmaceutical therapeutics coupled with the broad and deep expertise of BMS in oncology allows us to work together to bring forth this next wave of innovation in cancer therapy for patients. https://lnkd.in/gTEy-mC4

Look forward to catching up in NY, London, or Miami this month at the Truist, Jefferies London, or Evercore Healthcare conference https://lnkd.in/gxaTaMTE

Welcome our newest board member - Tim Van Hauwermeiren, CEO of argenx!

See you at ESMO in Madrid, Spain. On Sunday, Oct 22, we will have a poster presentation update on our ACTION-1 Phase 1b trial which is evaluating RYZ101 (Ac225 DOTATATE) in patients with refractory neuroendocrine tumors of the GI tract and pancreas. https://lnkd.in/d2Gb-vij

Thank you to our employees, board members, advisors/consultants, business partners, and investors for joining us on our journey to discover and develop innovative radiopharmaceutical therapies for patients with cancer. https://lnkd.in/gdwaPmKM

Thank you to Nasdaq for hosting us for the closing bell following our IPO

Congratulations to the RayzeBio team on the NASDAQ listing (RYZB) today.